ALEMBIC | ALEMBIC PHARMA | ALEMBIC/ ALEMBIC PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 60.0 | 16.7 | 358.9% | View Chart |
P/BV | x | 5.2 | 6.6 | 77.8% | View Chart |
Dividend Yield | % | 0.2 | 0.6 | 34.4% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC Mar-18 |
ALEMBIC PHARMA Mar-19 |
ALEMBIC/ ALEMBIC PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 72 | 664 | 10.8% | |
Low | Rs | 34 | 412 | 8.2% | |
Sales per share (Unadj.) | Rs | 4.7 | 208.7 | 2.3% | |
Earnings per share (Unadj.) | Rs | 6.1 | 31.0 | 19.7% | |
Cash flow per share (Unadj.) | Rs | 6.2 | 37.1 | 16.8% | |
Dividends per share (Unadj.) | Rs | 0.20 | 5.50 | 3.6% | |
Dividend yield (eoy) | % | 0.4 | 1.0 | 37.0% | |
Book value per share (Unadj.) | Rs | 40.7 | 144.2 | 28.2% | |
Shares outstanding (eoy) | m | 267.03 | 188.52 | 141.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 11.3 | 2.6 | 436.8% | |
Avg P/E ratio | x | 8.7 | 17.4 | 50.0% | |
P/CF ratio (eoy) | x | 8.5 | 14.5 | 58.5% | |
Price / Book Value ratio | x | 1.3 | 3.7 | 34.9% | |
Dividend payout | % | 3.3 | 17.7 | 18.5% | |
Avg Mkt Cap | Rs m | 14,139 | 101,461 | 13.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 207 | 7,467 | 2.8% | |
Avg. sales/employee | Rs Th | NM | NM | - | |
Avg. wages/employee | Rs Th | NM | NM | - | |
Avg. net profit/employee | Rs Th | NM | NM | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,255 | 39,347 | 3.2% | |
Other income | Rs m | 370 | 94 | 394.7% | |
Total revenues | Rs m | 1,625 | 39,441 | 4.1% | |
Gross profit | Rs m | 111 | 8,736 | 1.3% | |
Depreciation | Rs m | 38 | 1,152 | 3.3% | |
Interest | Rs m | 2 | 184 | 0.9% | |
Profit before tax | Rs m | 442 | 7,493 | 5.9% | |
Minority Interest | Rs m | 0 | 11 | 0.0% | |
Prior Period Items | Rs m | 1,212 | -93 | -1,306.0% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 24 | 1,568 | 1.5% | |
Profit after tax | Rs m | 1,630 | 5,844 | 27.9% | |
Gross profit margin | % | 8.9 | 22.2 | 39.9% | |
Effective tax rate | % | 5.4 | 20.9 | 25.9% | |
Net profit margin | % | 129.8 | 14.9 | 874.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,867 | 19,577 | 9.5% | |
Current liabilities | Rs m | 591 | 14,896 | 4.0% | |
Net working cap to sales | % | 101.6 | 11.9 | 854.4% | |
Current ratio | x | 3.2 | 1.3 | 240.3% | |
Inventory Days | Days | 94 | 90 | 105.0% | |
Debtors Days | Days | 74 | 45 | 162.2% | |
Net fixed assets | Rs m | 1,791 | 27,097 | 6.6% | |
Share capital | Rs m | 534 | 377 | 141.7% | |
"Free" reserves | Rs m | 10,324 | 26,811 | 38.5% | |
Net worth | Rs m | 10,858 | 27,188 | 39.9% | |
Long term debt | Rs m | 41 | 4,993 | 0.8% | |
Total assets | Rs m | 11,591 | 47,778 | 24.3% | |
Interest coverage | x | 260.9 | 41.7 | 625.6% | |
Debt to equity ratio | x | 0 | 0.2 | 2.1% | |
Sales to assets ratio | x | 0.1 | 0.8 | 13.1% | |
Return on assets | % | 14.1 | 12.6 | 111.6% | |
Return on equity | % | 15.0 | 21.5 | 69.8% | |
Return on capital | % | 15.2 | 23.6 | 64.4% | |
Exports to sales | % | 1.5 | 0 | - | |
Imports to sales | % | 21.0 | 0 | - | |
Exports (fob) | Rs m | 19 | NA | - | |
Imports (cif) | Rs m | 263 | NA | - | |
Fx inflow | Rs m | 19 | 19,453 | 0.1% | |
Fx outflow | Rs m | 264 | 6,065 | 4.4% | |
Net fx | Rs m | -244 | 13,388 | -1.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 236 | 8,120 | 2.9% | |
From Investments | Rs m | -224 | -7,556 | 3.0% | |
From Financial Activity | Rs m | -27 | 590 | -4.5% | |
Net Cashflow | Rs m | -15 | 1,153 | -1.3% |
Indian Promoters | % | 64.0 | 74.1 | 86.4% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.2 | 2.9 | 6.9% | |
FIIs | % | 9.7 | 9.1 | 106.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 26.1 | 13.9 | 187.8% | |
Shareholders | 54,701 | 49,328 | 110.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC With: DIVIS LABORATORIES WOCKHARDT AUROBINDO PHARMA FRESENIUS KABI ONCO. GLENMARK PHARMA
Compare ALEMBIC With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today as fears that the government could go for stricter lockdowns.
For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
More Views on NewsIn this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More